Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)
ConditionMetastatic Breast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorLund University Hospital
About this trial
Prospective multicenter observational study to assess molecular drivers of metastatic breast cancer and disease evolution upon therapeutic pressure.
The main aim is to develop and validate prognostic, predictive and pathogenic markers in clinically well-characterized population-based material of breast cancer tumors and the corresponding normal tissue.These data will be used to characterize recurrent breast cancer on a molecular level, study tumor evolution, develop biomarkers of response/resistance to targeted therapy in the metastatic setting, enroll patients on targeted treatment clinical studies and to elucidate mechanisms of resistance to therapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with pathologically confirmed advanced breast cancer (ABC), including locally advanced inoperable disease and stage IV disease.
Age > 18 years.
Performance status according to Eastern Cooperative Oncology Group (ECOG) ≤ 2.
ABC must be radiologically or clinically assessable, by means of at least one of the following techniques: clinical examination, computerized tomography (CT-scan), magnetic resonance imaging (MRI), bone scintigraphy or positron emission tomography (PET).
Disqualifiers
None
Trial population
Patients diagnosed with metastatic, inoperable breast cancer.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Biopsies, blood
Diagnostic testWe will perform targeted exon sequencing on paraffin embedded tissues from metastatic breast cancer
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Survival
Prospective recording of treatment interventions and molecular characteristics in metastatic breast cancer patients until the date of Death.
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov